Transplantation Proceedings
Volume 39, Issue 8 , Pages 2494-2500 , October 2007

Oxidative Stress in Cyclosporine-Induced Hypertension: Evidence of Beneficial Effects or Tolerance Development With Nitrate Therapy

  • F. Reis

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • ,
  • P. Rocha-Pereira

      Affiliations

    • Chemistry Department, Beira Interior University, Covilhã, Portugal
    • Molecular and Cellular Biology Institute, Porto University, Porto, Portugal.
    • ,
  • E. Teixeira de Lemos

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • ,
  • B. Parada

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal
    • ,
  • S. Baptista

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • ,
  • A. Figueiredo

      Affiliations

    • Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal
    • ,
  • A. Santos-Silva

      Affiliations

    • Biochemistry Service, Faculty of Pharmacy, Porto University, Porto, Portugal
    • Molecular and Cellular Biology Institute, Porto University, Porto, Portugal.
    • ,
  • C. Costa-Almeida

      Affiliations

    • Institute of Physiology, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • ,
  • A. Mota

      Affiliations

    • Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal
    • ,
  • F. Teixeira

      Affiliations

    • Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, Coimbra, Portugal
    • Corresponding Author InformationAddress reprint requests to Prof Frederico Teixeira, Therapeutics Unit, Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine, Coimbra University, 3004-504 Coimbra, Portugal.

References 

  1. Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999;20:437
  2. Olyaei AJ, de Mattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs. 1999;58:1011
  3. Martinez-Castelao A, Hueso M, Sanz V, et al. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl. 1998;68:130
  4. del Castillo D, Campistol JM, Guirado L, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl. 1998;68:135
  5. Cartier R, Dagenais F, Hollmann C, et al. Chronic exposure to cyclosporine affects endothelial and smooth muscle reactivity in the rat aorta. Ann Thorac Surg. 1994;58:789
  6. Rego A, Vargas R, Wroblewska B, et al. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J Pharmacol Exp Ther. 1990;252:165
  7. Santiago M, Reis F, Almeida L, et al. Impairment of vascular and platelet nitric oxide and 3′,5′ cyclic guanosine monophosphate content in cyclosporin A-induced hypertensive rats. Fund Clin Pharmacol. 2003;17:43
  8. Oriji GK, Keiser HR. Role of nitric oxide in cyclosporin A-induced hypertension. Hypertension. 1998;32:849
  9. Beckman J. The ABC’s of the reactions between nitric oxide, superoxide, peroxynitrite and superoxide dismutase (Oxygen 99—Sunrise Free Radical School 1). 1999;
  10. Beutler TM, Cottet-Maire F, Krauskopf A, et al. Does cyclosporin A generate free radicals?. TiPS. 2000;21:288
  11. Nishiyama A, Kobori H, Fukui T, et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension. 2003;42:754
  12. Zalba G, Beaumont FJ, San Jose G, et al. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. Nephrol Dial Transplant. 2001;16(suppl 1):2
  13. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248
  14. Miller NJ, Rice-Evans C, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond). 1993;84:407
  15. Bierig JG, Tolliver TJ, Catignani GL. Simultaneous determination of alpha-tocopherol and retinol in plasma or red cells by high pressure liquid chromatography. Ann J Clin Nutr. 1979;32:2143
  16. Saldeen T, Li D, Mehta JL. Differential effects of α- and γ-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. 1999;34:1208
  17. O’Neil GS, Chester AH, Kushwaha S, et al. Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br Heart J. 1991;66:212
  18. Stroes ES, Luscher TF, Groot FG, et al. Cyclosporin A increases nitric oxide activity in vivo. Hypertension. 1997;29:570
  19. Reis F, Santiago M, Almeida L, et al. Isosorbide-5-mononitrate and L-arginine effect on the cyclosporin-induced arterial hypertension and vascular nitric oxide impairment. In:  Tooke J,  Shore A,  Whatmore J editor. The Microcirculation and Vascular Biology. Bologna, Italy: Monduzzi Editore S.p.A; 2002;p. 257
  20. Reis F, Almeida L, Alcobia T, et al. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3′,5′-monophosphate disturbances. Thromb Res. 2003;110:107
  21. Reis F, Ponte L, Rocha L, et al. Curative isosorbide-5-mononitrate treatment, in opposition to the beneficial preventive one, aggravates the prothrombotic and proconstrictor state in cyclosporine-induced hypertensive rats. Clin Exp Pharmacol Physiol. 2005;32:640
  22. Horowitz JD. Tolerance induction during therapy with long-acting nitrates: how extensive is the “collateral damage”?. Cardiovasc Drug Ther. 2004;18:11
  23. Csont T, Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther. 2005;105:57
  24. Bartholomeusz B, Hardy KJ, Philips PA. Modulation of nitric oxide improves cyclosporin A-induced hypertension in rats and primates. J Hum Hypertens. 1998;12:839
  25. Lassila M, Santisteban J, Finckenberg P, et al. Vascular changes in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. J Physiol Pharmacol. 2001;52:21
  26. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?. Am J Physiol Heart Circ Physiol. 2001;281:981
  27. Stroes ES, Hijmering M, Zandvoort M, et al. Origin of superoxide production by nitric oxid synthase. FEBS Lett. 1998;438:161
  28. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxid synthase: the influence of cofactors. Proc Natl Acad Sci USA. 2000;95:9220
  29. de Lorgeril M, Boissonnat P, Salen P, et al. The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant recipients. Transplantation. 1994;58:193
  30. Parra-Cid T, Conejo Garcia JR, Carballo Alvarez F, et al. Antioxidant nutrients protect against CyA nephrotoxicity. Toxicology. 2003;189:99
  31. Brown AS, Moro MA, Masse JM, et al. Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite. Cardiovasc Res. 1998;40:380
  32. Graham A, Hogg N, Kalyanaraman B, et al. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 1993;330:181
  33. Watanabe H, Kakihama M, Ohtsuka S, et al. Randomized, double-blind, placebo-controlled study of supplemental vitamin C on attenuation of the development of nitrate tolerance. Circulation. 1998;97:886
  34. Schwemmer M, Bassenge E. New approaches to overcome tolerance to nitrates. Cardiovasc Drug Ther. 2003;17:159

PII: S0041-1345(07)00865-2

doi: 10.1016/j.transproceed.2007.07.030

Transplantation Proceedings
Volume 39, Issue 8 , Pages 2494-2500 , October 2007

Article Tools

* Image Usage & Resolution